Clinical Trial Update: Study to Evaluate MET409 Alone or in Combination With Empagliflozin in Patients With Type 2 Diabetes and NASH [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating MET409 alone or with empagliflozin in patients with type 2 diabetes and nonalcoholic steatohepatitis (NASH).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fatty Liver Disease
• Nonalcoholic Fatty Liver Disease
• Nonalcoholic Steatohepatitis
• Type 2 Diabetes Mellitus

Drugs mentioned

• Empagliflozin (empagliflozin)
• MET409

Snippet

Sponsor: Metacrine, Inc. | Conditions: NASH, NASH - Nonalcoholic Steatohepatitis | Phase 2 | Status: UNKNOWN